SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Approves Novartis Cosentyx for Polymyalgia Rheumatica

Story updates

02:43:14 AM UTC
SquawkNews
Novartis Cosentyx(R) becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
02:44:52 AM UTC
SquawkNews
Novartis: Cosentyx Becomes First And Only FDA-Approved Anti-IL-17 Biologic For Polymyalgia Rheumatica
02:46:41 AM UTC
SquawkNews
Basel, November 17, 2026 — Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticostero…
02:46:55 AM UTC
SquawkNews
The FDA approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. The release reports no financial terms or sales estimate.Material DetailsContext by AI AnalystThis is a commercial ex…

Related stories